The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global polymerase chain reaction market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 8% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Polymerase chain reaction (PCR) refers to a molecular diagnostic technique that is used to make multiple copies of a segment of DNA. A PCR machine is used to manipulate the temperature of the sample in an automatic and pre-programmed procedure to generate millions of copies of DNA sequencing accurately. This technology identifies and cultures disease-causing microorganisms, which aid in the detection of tuberculosis, Acquired Immunodeficiency Syndrome (AIDS), infections and Lyme disease. Owing to this, it finds extensive applications across various life science-related fields, such as genetics, biotechnology, molecular biology, drug discovery and clinical diagnostics.
Global Polymerase Chain Reaction Market Trends and Drivers:
The increasing prevalence of various infectious diseases and genetic disorders is one of the key factors driving the growth of the market. The rising geriatric population across the globe, which is more prone to chronic medical ailments, is also driving the industry growth. The outbreak of the coronavirus disease (COVID-19) pandemic has further led to the widespread adoption of PCR technologies for accurate diagnosis and early detection of infections. PCR devices also aid in minimizing the risks of contamination and the chances of human errors in the entire process.
The increasing demand for personalized and precision medicines is also creating a positive outlook for the market. These medicines aim to provide tailor-made therapies, which are identified and developed using PCR technologies. Other factors, including the increasing application in clinical diagnostics, along with extensive research and development (R&D) activities in the field of biotechnology, are expected to drive the market further.
IMARC Group provides an analysis of the key trends in each sub-segment of the global polymerase chain reaction market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on product and end user.
Breakup by Product:
Breakup by End User:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being Agilent Technologies Inc., BD (Becton, Dickinson and Company), BioMérieux (Institut Mérieux SA), Bio-RAD Laboratories Inc., F. Hoffmann-La Roche AG, Fluidigm Corporation, Merck KGaA, Perkinelmer Inc., Promega Corporation, Takara Bio Inc. and Thermo Fisher Scientific Inc.
|Base Year of the Analysis||2020|
|Segment Coverage||Product, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Agilent Technologies Inc., BD (Becton, Dickinson and Company), BioMérieux (Institut Mérieux SA), Bio-RAD Laboratories Inc., F. Hoffmann-La Roche AG, Fluidigm Corporation, Merck KGaA, Perkinelmer Inc., Promega Corporation, Takara Bio Inc. and Thermo Fisher Scientific Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at